TS alone has modest anti-tumor activity [21], and the observation that low doses of GV markedly potentiate modification of PRX3 by TS provides a combinatorial approach for inactivating the mitochondrial TR2/TRX2/PRX3 anti-oxidant network and inducing cytotoxicity (Fig. 8). The gene discussed is TXN2; the disease is neoplasm.